Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 95-106
Open Access | Times Cited: 90
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
Johan Burisch, Mirabella Zhao, Selwyn Odes, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 5, pp. 458-492
Open Access | Times Cited: 81
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Peter M. Irving, K Gecse
Gastroenterology (2022) Vol. 162, Iss. 5, pp. 1512-1524
Open Access | Times Cited: 73
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
Casper Webers, Augusta Ortolan, Alexandre Sepriano, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 130-141
Open Access | Times Cited: 72
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 53
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 45
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 760-774
Open Access | Times Cited: 16
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era
Gerasimos Evangelatos, Giorgos Bamias, George D. Kitas, et al.
Rheumatology International (2022) Vol. 42, Iss. 9, pp. 1493-1511
Open Access | Times Cited: 61
Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity
Marla C. Dubinsky, Michelle Mendiolaza, Becky L. Phan, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 9, pp. 1375-1385
Closed Access | Times Cited: 57
Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Nghia Nguyen, Virginia Solitano, Sudheer K. Vuyyuru, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 937-949.e2
Open Access | Times Cited: 45
Meta‐analysis: The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease
Sonika Sethi, Shiluka Dias, Aditi Kumar, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 12, pp. 1362-1374
Open Access | Times Cited: 43
Microneedle-based interstitial fluid extraction for drug analysis: Advances, challenges, and prospects
Shuwen Ma, Jiaqi Li, Lixia Pei, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 13, Iss. 2, pp. 111-126
Open Access | Times Cited: 38
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes
Julia Flammer, Tradite Neziraj, Stephan Rüegg, et al.
Drugs (2023) Vol. 83, Iss. 2, pp. 135-158
Open Access | Times Cited: 22
Model-informed precision dosing: State of the art and future perspectives
Iris K. Minichmayr, Erwin Dreesen, Marco Centanni, et al.
Advanced Drug Delivery Reviews (2024) Vol. 215, pp. 115421-115421
Open Access | Times Cited: 10
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
Thanaboon Chaemsupaphan, Rupert W. Leong, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1234-1243
Open Access | Times Cited: 8
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Marthe Kirkesæther Brun, Johanna Elin Gehin, K. H. Bjørlykke, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 4, pp. e226-e236
Closed Access | Times Cited: 7
High-throughput, low-cost quantification of 11 therapeutic antibodies using caprylic acid precipitation and LC-MS/MS
Erik I. Hallin, Trond Trætteberg Serkland, Tormod Bjånes, et al.
Analytica Chimica Acta (2024) Vol. 1313, pp. 342789-342789
Open Access | Times Cited: 7
Switching Among Biosimilars: A Review of Clinical Evidence
Eleonora Allocati, Brian Godman, Marco Gobbi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 30
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Thea H. Wiken, Marte Lie Høivik, L. Buer, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 58, Iss. 8, pp. 863-873
Open Access | Times Cited: 19
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
Samuel Bitoun, Signe Hässler, David Ternant, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2323098-e2323098
Open Access | Times Cited: 17
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Namita Singh, Marla C. Dubinsky
Springer eBooks (2023), pp. 445-456
Closed Access | Times Cited: 16
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Basket, Umbrella, and Platform Trials: The Potential for Master Protocol–Based Trials in Inflammatory Bowel Disease
Sailish Honap, Bruce E. Sands, Vipul Jairath, et al.
Gastroenterology (2024) Vol. 167, Iss. 4, pp. 636-642.e2
Open Access | Times Cited: 5
Tumour necrosis factor inhibitors in Ulcerative colitis: real-world data on Therapeutic drug monitoring and evaluation of current treatment targets (STRIDE II)
J A Lundekvam, Marte Lie Høivik, Karoline Anisdahl, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top